Head to Head Review: NewAmsterdam Pharma (NAMS) versus The Competition

NewAmsterdam Pharma (NASDAQ:NAMS) is one of 1,078 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare NewAmsterdam Pharma to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.

Insider and Institutional Ownership

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 13.5% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares NewAmsterdam Pharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
NewAmsterdam Pharma Competitors	-3,399.87%	-235.11%	-32.77%

Earnings & Valuation

This table compares NewAmsterdam Pharma and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NewAmsterdam Pharma	$47.14 million	-$176.94 million	-10.90
NewAmsterdam Pharma Competitors	$9.91 billion	$136.15 million	-5.39

NewAmsterdam Pharma’s rivals have higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

NewAmsterdam Pharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma’s rivals have a beta of 4.18, indicating that their average share price is 318% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for NewAmsterdam Pharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0	0	7	0	3.00
NewAmsterdam Pharma Competitors	8824	22869	51334	1438	2.54

NewAmsterdam Pharma presently has a consensus target price of $43.00, indicating a potential upside of 109.76%. As a group, “Pharmaceutical preparations” companies have a potential upside of 2,433.84%. Given NewAmsterdam Pharma’s rivals higher probable upside, analysts plainly believe NewAmsterdam Pharma has less favorable growth aspects than its rivals.

Summary

NewAmsterdam Pharma beats its rivals on 7 of the 13 factors compared.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.